Global Parkinson's Genetics Program Data Release 8

In September 2024, GP2 announced the eighth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 5,481 additional whole genome sequences and 10,454 clinical exome sequences. Additional genotyping will be provided in the following release.

• The whole genome sequencing (WGS) data now consists of a total of 7,734 sequenced participants (6,113 PD cases, 617 Controls, and 1,004 ‘Other’ phenotypes).

• When removing the locally-restricted samples, these now consist of 4,713 participants (4,098 PD cases, 390 Controls, and 225 ‘Other’ phenotypes).

• Of note, cases recruited via the Monogenic network are coded as ‘Other’

• Additionally, included in this WGS release is a partial release of whole genome sequences from two AMP-PD cohorts (BioFind and PPMI) that have been joint-called with GP2 WGS. Released samples can be linked back to the original AMP-PD IDs through an ID crosswalk file included with the release.

• This release also includes 10,454 joint-called clinical exome sequencing (CES) participants from the Parkinson’s Foundation.

• This release includes a total of 62,087 individuals who have core clinical data available. Among these, 16,800 individuals have deep clinical phenotyping and genetic data available

---

Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.13755496, release 8) used in the preparation of this article were obtained from the Global Parkinson’s Genetics Program (GP2)."